In the ever-evolving world of life sciences, policy decisions can make or break the progress of our member companies. HINJ is deeply invested in engaging federal & state policies in areas such as research funding, regulatory reforms, & patient access: hinj.org/advocacy/

New Jersey’s life sciences are the beating heart of our state’s workforce and economy – an industry that is helping patients around the world by finding cures here in New Jersey. Learn more from HINJ President and CEO Chrissy Buteas in New Jersey Globe: newjerseyglobe.com/health/chrissy…

Life sciences continues to drive advances in human health as FDA approves Pfizer Inc.'s new one-time gene therapy for Hemophilia. Read more here: businesswire.com/news/home/2024…

#ICYMI : Information Technology and Innovation Foundation's recent report offers several solutions for U.S. policymakers to counter China’s rising biopharmaceutical competitiveness: Invest in robust R&D, restore a strong #IP environment and avoid government drug price controls. Read more here: itif.org/publications/2…

HINJ is proud to represent a number of life sciences companies dedicated to reshaping corporate culture through their DEI initiatives – addressing emerging social, governance & workplace trends that reflect the evolution of societal standards. Learn more: hinj.org/dei/

Excellent piece by Senator Bagger on the tremendous health and economic benefits derived from NJ’s life sciences, and ways we can lower costs for patients without jeopardizing the discovery of new treatments and cures. Read more in NJ Spotlight News: njspotlightnews.org/2024/04/op-ed-…

Congressman Donald Payne, Jr. was a highly effective public servant and also a wonderful human being. Our thoughts are with his family, his staff, and the many, many people whose lives he touched. He will be dearly missed. Read more from New Jersey Globe: newjerseyglobe.com/in-memoriam/do…

SAVE THE DATE: HINJ is proud to partner with Morris NJ Chamber & Morris County EDC for the Life Sciences Forum on 5/8 from 8:30-10 a.m. at Gilead Sciences in #Parsippany – featuring speakers from Gilead, Zimmer Biomet, Ferring & more. Learn more & register online: web.morrischamber.org/events/Life-Sc…

This past weekend, HINJ’s SVP – State Affairs Haskell Berman delivered remarks at the 69th Annual Meeting of the NJAS (NJAS) at Kean University . Learn more about NJAS here: njas.org.

#DYK : For more than 135 years, NJ continues to be a global hub for the biopharmaceutical & medtech sector? The state is home to 14 of the world's top 20 research-based biopharmaceutical companies & 12 of the top 20 medtech companies. Learn more: hinj.org

While #biosimilars are increasingly driving competition and savings, some challenges are keeping the biosimilar marketplace from realizing its full potential. Visit our partner We Work For Health's resources page to learn more: weworkforhealth.org/resources

Our member company Bristol Myers Squibb recently released its latest Environmental, Social and Governance (ESG) Report highlighting positive changes for patients and the communities they serve worldwide. Check out the full report here: esg.bms.com

HINJ recently attended the Mercer NJBIA Employer Legislative Committee meeting hosted by Princeton Mercer Regional Chamber. Here, HINJ’s Haskell Berman connected with local legislators including Speaker Craig J. Coughlin, networked with colleagues & learned about issues affecting the industry.

This week is #MedicalLaboratoryProfessionals Week – recognizing and celebrating the medical laboratory professionals and pathologists who play a vital role in health care and patient advocacy. We thank you for your hard work!

HINJ had the opportunity to attend the NJ AI Summit, hosted by Princeton University in partnership with New Jersey Governor Phil Murphy and the New Jersey EDA. Pictured is Assemblyman Chris Tully, Chairman of the Assembly Science, Innovation and Technology Committee with HINJ’s Haskell Berman.

Rather than attacking “Big Pharma,” U.S. policymakers should focus on how to win the global battle for biopharmaceutical industry competitiveness as China’s threat continues to rise. Read more in Information Technology and Innovation Foundation's new report: itif.org/publications/2…

New Jersey’s biopharmaceutical and medical technology companies make significant contributions to New Jersey’s economy, with $118.2 billion in total economic impact. Learn more about the facts and figures of the life sciences industry here: hinj.org/new-jersey-by-…

#DYK : Newly appointed President and CEO Chrissy Buteas will be the HealthCare Institute of New Jersey’s fourth President and CEO? Learn more about Chrissy and her professional career here: hinj.org/staff/

Dive into the numbers behind innovation: We Work For Health recently unveiled the latest data on America’s biopharmaceutical vendors, which support 4.9M+ jobs and $71.6B+ in 2022 spending across the country. Click here to explore the findings: weworkforhealth.org/in-the-states

#REMINDER : There’s still time to register for MDMA' Annual Meeting from 4/17-4/19 in Washington, DC. Attendees will hear from Congressional, Federal Agency & industry leaders on current & future issues impacting our industry. Register here: medicaldevices.org/events/EventDe…